Incremental total cost compared with gFOBT, mean (£) (95% CI) | Incremental life years compared with gFOBT, mean (95% CI) | Incremental QALYs compared with gFOBT, mean (95% CI) | ICER: incremental cost per QALY gained compared with gFOBT (£)* | Incremental net benefit compared with gFOBT, mean (£) (95% CI)** | |

FIT 180 µg Hb/g faeces (base case) | −27 (−43 to -12) | 0.019 (0.016 to 0.023) | 0.014 (0.012 to 0.017) | FIT dominates (p<0.001) | 315 (256 to 377) |

FIT 150 µg Hb/g faeces | −40 (−62 to -19) | 0.028 (0.024 to 0.032) | 0.021 (0.018 to 0.024) | FIT dominates (p<0.001) | 458 (388 to 531) |

FIT 100 µg Hb/g faeces | −53 (−86 to -23) | 0.038 (0.033 to 0.043) | 0.029 (0.025 to 0.033) | FIT dominates (p<0.001) | 637 (546 to 731) |

FIT 40 µg Hb/g faeces | −84 (−151 to -24) | 0.073 (0.065 to 0.082) | 0.058 (0.051 to 0.064) | FIT dominates (p<0.005) | 1237 (1072 to 1405) |

FIT 20 µg Hb/g faeces | −62 (−141 to 8) | 0.082 (0.072 to 0.091) | 0.066 (0.057 to 0.074) | FIT dominates (p<0.050) | 1378 (1177 to 1582) |

Means are deterministic means; all 95% CIs calculated as percentiles of 1000 probabilistic model runs.

*Incremental cost-effectiveness ratio (ICER)=ΔC/ΔE, where ΔE and ΔC are the incremental QALYs and incremental costs, respectively, of FIT compared with gFOBT. p -values calculated as the proportion of the 1000 PSA simulations with positive ICERs.

**INB= λ.ΔE – ΔC, where λ is the willingness to pay threshold=£20 000 per QALY gained.

FIT, faecal immunochemical test; gFOBT, guaiac faecal occult blood test; QALY, quality-adjusted life years.